AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions
MWN-AI** Summary
AIM ImmunoTech Inc. announced the publication of final clinical study results from its AMP-518 trial, aimed at assessing the efficacy and safety of Ampligen in treating post-COVID conditions, particularly fatigue. The results were made available on ClinicalTrials.gov and underscore AIM’s confidence in Ampligen as a viable therapeutic solution for moderate-to-severe fatigue associated with Long COVID. AIM's CEO, Thomas K. Equels, emphasized the significant findings from the study, highlighting that patients treated with Ampligen exhibited a meaningful improvement in their walking distance during a Six-Minute Walk Test (6MWT) compared to those on placebo, particularly noted in patients with baseline walking distances under 205 meters.
These promising results, aligned with a recent analysis from the NIH’s RECOVER initiative linking Long COVID to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), indicate an alarming rise in patients meeting ME/CFS criteria post-pandemic, showing five times the prevalence compared to pre-pandemic levels. This increase points to a pressing need for effective therapies, as many have suffered debilitating effects from these conditions.
The AMP-518 trial's analysis revealed potential target demographics for future studies, which AIM plans to focus on in upcoming clinical trials. The company's commitment to addressing this unmet medical need is critical, especially as it collaborates with public sectors to develop solutions for patients impacted by COVID-related fatigue. AIM's innovative therapeutic approach with Ampligen could provide relief to many who have long endured the challenges of ME/CFS as a consequence of their COVID-19 infections.
MWN-AI** Analysis
AIM ImmunoTech Inc. (NYSE American: AIM) recently announced the publication of its final clinical study results from the AMP-518 trial, exploring the efficacy of Ampligen as a potential therapeutic for individuals suffering from post-COVID conditions, specifically Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). With a significant increase in post-COVID fatigue cases, now testable via the Six-Minute Walk Test (6MWT), AIM presents a potentially robust investment opportunity for stakeholders in the biotech sector.
From a market perspective, AIM's promising topline data indicates that Ampligen may offer tangible benefits over placebo, with improvements in mobility and a clear statistical signal (p < 0.02). This could substantiate AIM's foothold in a burgeoning market concerning long-term COVID effects, aligning with rising healthcare needs.
Investors should closely monitor AIM’s subsequent clinical trials aimed at leveraging the identified patient demographics likely to respond favorably. The correlation between COVID-19 and increased ME/CFS cases underscores a critical public health need, raising the likelihood of regulatory support that could facilitate Ampligen's pathway to approval.
However, potential investors must also remain cognizant of the inherent risks. Clinical trials are fraught with uncertainties, and past successes do not guarantee regulatory approval or market acceptance. The cautionary statements issued by AIM highlight the volatility associated with biopharmaceutical companies, emphasizing the necessity to tread carefully while taking positions in AIM stock.
In conclusion, while AIM ImmunoTech presents an intriguing opportunity given its focus on an unmet medical need, prospective investors should balance enthusiasm for the upside potential with a vigilant approach to the associated risks in the biotech landscape.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
OCALA, Fla., Jan. 23, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the final Clinical Study Results for the “Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions” (“AMP-518”) was posted yesterday to ClinicalTrials.gov (See: NCT05592418 ).
CEO Thomas K. Equels stated: “The results of AMP-518 support AIM’s belief in Ampligen as a potential therapeutic for people with the moderate-to-severe Post-COVID condition of fatigue. Our analysis of the final Clinical Study Results has helped us to identify a likely subject population that would experience the greatest benefit from Ampligen in AIM’s planned follow-up clinical trial. The AMP-518 data also comes on the heels of a new analysis of data that was generated through the National Institutes of Health RECOVER initiative, demonstrating a clear link between Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. The report found that the prevalence of patients who met the 2015 Institute of Medicine ME/CFS clinical diagnostic criteria is five times higher than before the start of the COVID-19 pandemic. This means there has been a considerable increase in the number of patients that could be classified as having ME/CFS resulting from their COVID-19 infection. Hundreds of thousands of people have suffered from the painful and debilitating disorder of ME/CFS over the decades. With the growing reality of COVID-induced ME/CFS, it is now more important than ever that companies such as AIM and the public sector work together to develop meaningful therapies. We must take action to solve this unmet need, and not let another generation be lost to the ravages of ME/CFS.”
AIM had previously reported positive topline results from its AMP-518 Phase 2 clinical trial. In further analyzing the results of AMP-518, AIM determined that, in this study, Ampligen-treated patients with Long COVID were, on average, able to walk farther in a Six-Minute Walk Test (“6MWT”) when compared to subjects who received a placebo. The 6MWT measured the distance a subject was able to walk in six minutes as a baseline and then again at 13 weeks. A clear signal of significant potential (p <0.02, two-tailed T-test) was observed in Ampligen-treated subjects with a baseline 6MWT less than 205 meters, who saw a mean improvement of 139 meters, compared to a mean improvement of 91 meters in the corresponding part of the group who received the placebo. AIM therefore believes that any future trial design should focus on Ampligen’s therapeutic potential for subjects whose COVID-related fatigue or ME/CFS symptoms can be categorized as moderate or worse.
Read AIM’s January 22, 2025 press release: “ AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS ”
Read “ Incidence and Prevalence of Post-COVID-19 Myalgic Encephalomyelitis: A Report from the Observational RECOVER-Adult Study ” in the Journal of General Internal Medicine .
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen ® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X , LinkedIn , and Facebook .
Cautionary Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy for Long COVID or ME/CFS. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
Investor Contact:JTC Team, LLCJenene Thomas908.824.0775AIM@jtcir.com
FAQ**
What specific findings from the AMP-5study support the therapeutic potential of Ampligen for moderate-to-severe fatigue related to Long COVID, according to AIM ImmunoTech Inc. AIM's CEO Thomas K. Equels?
How does the increased prevalence of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) post-COVID, as reported by AIM ImmunoTech Inc. AIM, impact the future clinical trial designs for Ampligen?
Based on the clinical results posted by AIM ImmunoTech Inc. AIM, how do the improvements observed in the Six-Minute Walk Test (6MWT) for Ampligen-treated patients compare with those in the placebo group?
What are the key risks and uncertainties associated with the forward-looking statements made by AIM ImmunoTech Inc. AIM regarding the approval of Ampligen as a potential therapy for Long COVID and ME/CFS?
**MWN-AI FAQ is based on asking OpenAI questions about AIM ImmunoTech Inc. (NYSE: AIM).
NASDAQ: AIM
AIM Trading
57.55% G/L:
$0.4038 Last:
448,184,778 Volume:
$0.2756 Open:
